BEIGF insider trades ADS under 10b5-1 plan; options cover 127,062 shares
Rhea-AI Filing Summary
BeOne Medicines Ltd. reporting person Lee Chan Henry (SVP, General Counsel) disclosed multiple transactions in American Depositary Shares (ADS) and options on 10/08/2025. The filing shows several sales under a Rule 10b5-1 plan adopted 05/14/2025, including weighted-average sale prices around $350 and $351. Offsetting purchases and transfers of ADS occurred the same day at prices between $159.03 and $213.32. After those transactions the reporting person holds 9,559 ADS equivalent and direct beneficial ownership in 223,106 ordinary shares. The report also discloses exercise/vesting schedules for outstanding options totaling 127,062 ordinary shares exercisable through 06/04/2034, with stated exercise prices shown in the filing.
Positive
- Sales executed under a Rule 10b5-1 plan adopted on 05/14/2025, which documents a prearranged trading program
- Reporting person retains material equity and option exposure: 223,106 ordinary shares and options covering 127,062 ordinary shares, indicating continued ownership stake
Negative
- Multiple sizable ADS sales on 10/08/2025 at weighted-average prices near $350, reducing immediate stake
- Outstanding options total potential dilution of at least 127,062 ordinary shares exercisable through 06/04/2034
Insights
Insider executed multiple ADS sales under a 10b5-1 plan while retaining sizable option exposure.
The filing records contemporaneous sales and acquisitions of American Depositary Shares on 10/08/2025, with sales disclosed at weighted-average prices near $350 and $351. The reporter states the sales were effected under a Rule 10b5-1 plan adopted on 05/14/2025, which provides an affirmative defense for pre‑arranged trades.
Material dependencies include continued vesting of options through 06/04/2034 and the reporting person's residual equity: 223,106 ordinary shares beneficially owned and options covering 127,062 ordinary shares. Near-term items to watch are future scheduled vesting dates and any additional 10b5-1 plan transactions that would change listed holdings.
Significant option grants remain outstanding with multi-year vesting schedules and zero stated option price in the filing summary.
The report lists three option awards that, when converted, underlie 3,926, 116,493, and 3,848 ordinary shares respectively, with exercise prices disclosed (e.g., $14.96, $16.41, $12.23) and vesting schedules spanning four years from grant dates in 2023 and 2024.
These awards create future dilution potential as they vest and become exercisable through 08/04/2032, 06/14/2033, and 06/04/2034. Monitor net share count changes as options vest and any exercises are reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Share Option (Right to Buy) | 3,926 | $0.00 | -- |
| Exercise | Share Option (Right to Buy) | 116,493 | $0.00 | -- |
| Exercise | Share Option (Right to Buy) | 3,848 | $0.00 | -- |
| Sale | American Depositary Shares | 1,112 | $350.00 | $389K |
| Exercise | American Depositary Shares | 302 | $194.47 | $59K |
| Exercise | American Depositary Shares | 8,961 | $213.32 | $1.91M |
| Exercise | American Depositary Shares | 296 | $159.03 | $47K |
| Sale | American Depositary Shares | 664 | $347.82 | $231K |
| Sale | American Depositary Shares | 4,733 | $350.2177 | $1.66M |
| Sale | American Depositary Shares | 4,162 | $351.1232 | $1.46M |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (1)
- Each American Depositary Share represents 13 Ordinary Shares. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.00 to $350.98, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.00 to $351.53, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
